Court May Ask Roche To Pay Amgen 22.5 Percent Mircera Marketing Royalty
This article was originally published in The Pink Sheet Daily
Executive Summary
Preliminary injunction bars launch of Roche’s Mircera; suggests terms to avoid a permanent injunction.
You may also be interested in...
Roche Wins Ruling On Mircera Importation; Court to Hear Injunction Appeal
Although it may not make much difference for its follow-on biologic Mircera (epoetin beta), Roche has won a battle with Amgen that could affirm a layer of intellectual property protection for all follow-on biologics in the U.S
Roche Wins Ruling On Mircera Importation; Court to Hear Injunction Appeal
Although it may not make much difference for its follow-on biologic Mircera (epoetin beta), Roche has won a battle with Amgen that could affirm a layer of intellectual property protection for all follow-on biologics in the U.S
Roche Agrees To Court Conditions For Mircera Launch
Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.